Literature DB >> 9679543

Regulation of rat glutathione S-transferase A5 by cancer chemopreventive agents: mechanisms of inducible resistance to aflatoxin B1.

J D Hayes1, D J Pulford, E M Ellis, R McLeod, R F James, J Seidegård, E Mosialou, B Jernström, G E Neal.   

Abstract

The rat can be protected against aflatoxin B1 (AFB1) hepatocarcinogenesis by being fed on a diet containing the synthetic antioxidant ethoxyquin. Evidence suggests that chemoprotection against AFB1 is due to increased detoxification of the mycotoxin by one or more inducible drug-metabolising enzymes. The glutathione S-transferase (GST) isoenzymes in rat liver that contribute to ethoxyquin-induced chemoprotection against AFB1 have been identified by protein purification. This approach resulted in the isolation of several heterodimeric class alpha GST, all of which contained the A5 subunit and possessed at least 50-fold greater activity towards AFB1-8,9-epoxide than previously studied transferases. Molecular cloning and heterologous expression of rat GSTA5-5 has led to the demonstration that it exhibits substantially greater activity for AFB1-8,9-epoxide than other rat transferases. The A5 homodimer can also catalyse the conjugation of glutathione with other epoxides, such as trans-stilbene oxide and 1,2-epoxy-3-(4'-nitrophenoxy)propane, and possesses high catalytic activity for the reactive aldehyde 4-hydroxynonenal. Western blotting has shown that the A5 subunit is not only induced by ethoxyquin but that it is also induced by other cancer chemopreventive agents, such as butylated hydroxyanisole, oltipraz, benzyl isothiocyanate, indole-3-carbinol and coumarin. In addition to GSTA5, we have identified a novel aflatoxin-aldehyde reductase (AFAR) that is similarly induced by ethoxyquin. However, immunoblotting has shown that GSTA5 and AFAR are not always co-ordinately regulated by chemoprotectors. In order to gain a better understanding of the mechanisms responsible for the induction of GSTA5 protein, the GSTA5 gene has been cloned. It was isolated on two overlapping bacteriophage lambda clones and found to be approximately 12 kb in length. The transcriptional start site of GSTA5 has been identified 228 bp upstream from the ATG translational initiation codon. Computer-assisted analysis of the upstream sequence has indicated the presence of a putative antioxidant responsive element (located between -421 and -429 bp) which may be responsible for the induction of GSTA5 by chemopreventive agents.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9679543     DOI: 10.1016/s0009-2797(97)00151-8

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  18 in total

1.  Sulforaphane- and phenethyl isothiocyanate-induced inhibition of aflatoxin B1-mediated genotoxicity in human hepatocytes: role of GSTM1 genotype and CYP3A4 gene expression.

Authors:  Kerstin Gross-Steinmeyer; Patricia L Stapleton; Julia H Tracy; Theo K Bammler; Stephen C Strom; David L Eaton
Journal:  Toxicol Sci       Date:  2010-05-04       Impact factor: 4.849

2.  4-Hydroxy-2(E)-nonenal enantiomers: (S)-selective inactivation of glyceraldehyde-3-phosphate dehydrogenase and detoxification by rat glutathione S-transferase A4-4.

Authors:  A Hiratsuka; K Hirose; H Saito; T Watabe
Journal:  Biochem J       Date:  2000-08-01       Impact factor: 3.857

3.  (S)-preferential detoxification of 4-hydroxy-2(E)-nonenal enantiomers by hepatic glutathione S-transferase isoforms in guinea-pigs and rats.

Authors:  A Hiratsuka; K Tobita; H Saito; Y Sakamoto; H Nakano; K Ogura; T Nishiyama; T Watabe
Journal:  Biochem J       Date:  2001-04-01       Impact factor: 3.857

4.  Sulforaphane, a cancer chemopreventive agent, induces pathways associated with membrane biosynthesis in response to tissue damage by aflatoxin B1.

Authors:  Nirachara Techapiesancharoenkij; Jeannette L A Fiala; Panida Navasumrit; Robert G Croy; Gerald N Wogan; John D Groopman; Mathuros Ruchirawat; John M Essigmann
Journal:  Toxicol Appl Pharmacol       Date:  2014-11-18       Impact factor: 4.219

5.  Pharmacogenomics of phenolic antioxidant butylated hydroxyanisole (BHA) in the small intestine and liver of Nrf2 knockout and C57BL/6J mice.

Authors:  Sujit Nair; Changjiang Xu; Guoxiang Shen; Vidya Hebbar; Avantika Gopalakrishnan; Rong Hu; Mohit Raja Jain; Wen Lin; Young-Sam Keum; Celine Liew; Jefferson Y Chan; Ah-Ng Tony Kong
Journal:  Pharm Res       Date:  2006-09-13       Impact factor: 4.200

6.  Testing an aflatoxin B1 gene signature in rat archival tissues.

Authors:  B Alex Merrick; Scott S Auerbach; Patricia S Stockton; Julie F Foley; David E Malarkey; Robert C Sills; Richard D Irwin; Raymond R Tice
Journal:  Chem Res Toxicol       Date:  2012-05-04       Impact factor: 3.739

7.  Multidrug resistance protein MRP1 protects against the toxicity of the major lipid peroxidation product 4-hydroxynonenal.

Authors:  J Renes; E E de Vries; G J Hooiveld; I Krikken; P L Jansen; M Müller
Journal:  Biochem J       Date:  2000-09-01       Impact factor: 3.857

8.  Modulation of aflatoxin B1-mediated genotoxicity in primary cultures of human hepatocytes by diindolylmethane, curcumin, and xanthohumols.

Authors:  Kerstin Gross-Steinmeyer; Patricia L Stapleton; Julia H Tracy; Theo K Bammler; Stephen C Strom; Donald R Buhler; David L Eaton
Journal:  Toxicol Sci       Date:  2009-09-21       Impact factor: 4.849

9.  Structural and functional divergence of GDAP1 from the glutathione S-transferase superfamily.

Authors:  Matthew R Googins; Aigbirhemwen O Woghiren-Afegbua; Michael Calderon; Claudette M St Croix; Kirill I Kiselyov; Andrew P VanDemark
Journal:  FASEB J       Date:  2020-04-10       Impact factor: 5.834

10.  New dicoumarol sodium compound: crystal structure, theoretical study and tumoricidal activity against osteoblast cancer cells.

Authors:  Sadia Rehman; Muhammad Ikram; Ajmal Khan; Soyoung Min; Effat Azad; Thomas S Hofer; Kh Mok; Robert J Baker; Alexander J Blake; Saeed Ur Rehman
Journal:  Chem Cent J       Date:  2013-07-02       Impact factor: 4.215

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.